Sean C. Blackwell

Sean C. Blackwell


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2019 in American Journal of Perinatology
Verified
Journal Article
Open access
PDF file
SBSean C. Blackwell
Sean C. Blackwell
CGCynthia Gyamfi-Bannerman
Cynthia Gyamfi-Bannerman
JBJoseph R. Biggio
Joseph R. Biggio
SCSuneet P. Chauhan
Suneet P. Chauhan
BHBrenna L. Hughes
Brenna L. Hughes
JKJulie Krop
Julie Krop
Background Women with a history of spontaneous preterm birth (SPTB) are at a significantly increased risk for recurrent preterm birth (PTB). To date, only one large U.S. clinical trial comparing 17-OHPC (17-α-hydroxyprogesterone caproate or “17P”) to placebo has been published, and this trial was stopped early due to a large treatment benefit. Objective This study aimed to assess whether 17-OHPC decreases recurrent PTB and neonatal morbidity in women with a prior SPTB in a singleton gestation. Study Design This was a double-blind, placebo-controlled international trial involving women with a previous singleton SPTB (clinicaltrials.gov: NCT 01004029). Women were enrolled at 93 clinical centers (41 in the United States and 52 outside the United States) between 160/7 to 206/7 weeks in a 2:1 ratio, to receive either weekly intramuscular (IM) injections of 250 mg of 17-OHPC or an inert oil placebo; treatment was continued until delivery or 36 weeks. Co-primary outcomes were PTB < 35 weeks and a neonatal morbidity composite index. The composite included any of the following: neonatal death, grade 3 or 4 intraventricular hemorrhage, respiratory distress syndrome, bronchopulmonary dysplasia, necrotizing enterocolitis, or proven sepsis. A planned sample size of 1,707 patients was estimated to provide 98% power to detect a 30% reduction in PTB < 35 weeks (30% to 21%) and 90% power to detect a 35% reduction in neonatal composite index (17%–11%) using a two-sided type-I error of 5%. Finally, this sample size would also provide 82.8% power to rule out a doubling in the risk of fetal/early infant death assuming a 4% fetal/early infant death rate. Analysis was performed according to the intention-to-treat principle. Results Baseline characteristics between the 1,130 women who received 17-OHPC and 578 women who received placebo were similar. Overall, 87% of enrolled women were Caucasian, 12% had >1 prior SPTB, 7% smoked cigarettes, and 89% were married/lived with partner. Prior to receiving study drug, 73% women had a transvaginal cervical length measurement performed and <2% had cervical shortening <25 mm. There were no significant differences in the frequency of PTB < 35 weeks (17-OHPC 11.0% vs. placebo 11.5%; relative risk = 0.95 [95% confidence interval (CI): 0.71–1.26]) or neonatal morbidity index (17-OHPC 5.6% vs. placebo 5.0%; relative risk = 1.12 [95% CI: 0.68–1.61]). There were also no differences in frequency of fetal/early infant death (17-OHPC 1.7% vs. placebo 1.9%; relative risk = 0.87 [95% CI: 0.4–1.81]. Maternal outcomes were also similar. In the subgroup of women enrolled in the United States (n = 391; 23% of all patients), although the rate of PTB < 35 weeks was higher than the overall study population, there were no statistically significant differences between groups (15.6% vs. 17.6%; relative risk = 0.88 [95% CI: 0.55, 1.40]. Conclusion In this study population, 17-OHPC did not decrease recurrent PTB and was not associated with increased fetal/early infant death. In women with a prior spontaneous preterm birth, weekly 17-OHPC compared with placebo did not reduce recurrent preterm birth or decrease neonatal morbidity. Date of registration: October 27, 2009. Date of initial participant enrollment: November 12, 2009. Clinical trials ID: NCT01004029. URL: https://clinicaltrials.gov/ct2/show/NCT01004029?term=17P+AMAG&rank=2.

1 December 2016 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
SBSean C. Blackwell
Sean C. Blackwell
MLMark B. Landon
Mark B. Landon
LMLisa ScM Mele
Lisa ScM Mele
URUma M. Reddy
Uma M. Reddy
BCBrian M. Casey
Brian M. Casey
FNfor the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network
for the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network
OBJECTIVE: To evaluate the relationships among excessive gestational weight gain, neonatal adiposity, and adverse obstetric outcomes in women with mild gestational diabetes mellitus. METHODS: This is a secondary analysis of a multicenter randomized clinical trial of women with mild gestational diabetes mellitus. Based on self-reported prepregnancy body weight, gestational weight gain was categorized as excessive if it was greater than 2009 Institute of Medicine guidelines. Maternal outcomes and neonatal anthropomorphic characteristics were compared between women with excessive weight gain and those without excessive weight gain. Multiple linear and logistic regression analyses were performed to adjust for confounding factors. RESULTS: We studied 841 women who participated in the main trial and had prepregnancy body mass index (BMI) and delivery information available (n=431 treatment group, n=410 no treatment). After adjustment for factors including treatment and prepregnancy BMI, excessive weight gain remained associated with large for gestational age (adjusted odds ratio [OR] 2.94, 95% confidence interval [CI] 1.81–4.93), birth weight greater than 4,000 g (adjusted OR 2.56, 95% CI 1.54–4.40), preeclampsia (adjusted OR 2.96, 95% CI 1.35–7.03), and cesarean delivery for labor arrest (adjusted OR 2.37, 95% CI 1.30–4.44). In addition, excessive weight gain was independently associated with increased total neonatal fat (P<.001) and birth weight (P<.001). CONCLUSION: In women with both treated and untreated mild gestational diabetes mellitus, excessive gestational weight gain was independently associated with both greater birth weight and adiposity.

17 November 2011 in American Journal of Perinatology
Verified
Journal Article
Closed access
PDF file
JRJerrie S. Refuerzo
Jerrie S. Refuerzo
AGAmbica Garg
Ambica Garg
BRBarbara Rech
Barbara Rech
SRSusan M. Ramin
Susan M. Ramin
AVAlex Vidaeff
Alex Vidaeff
SBSean C. Blackwell
Sean C. Blackwell
To compare the timing, duration, and severity of corticosteroid-associated hyperglycemia in pregnant women with and without diabetes mellitus (DM). An observational study was conducted of pregnant women with DM and controls who received corticosteroids. Median glucose levels were calculated over 4-hour intervals after the first dose of corticosteroid with a continuous glucose monitor. A glucose level increase of at least 15% above baseline was considered significant. Nine pregnant women participated in this study (six with DM and three without DM). Elevations of glucose levels occurred at hour 20, 44, and 68 in both groups and lasted for up to 4 hours. In those with DM, glucose levels increased 33 to 48%, whereas in those without DM, glucose levels rose 16 to 33%. Several, relatively short episodes of glucose elevation occur in response to corticosteroids, and are more pronounced in diabetic women.

1 October 2011 in Seminars in Perinatology
Verified
Journal Article
Closed access
SBSean C. Blackwell
Sean C. Blackwell

24 December 2024 in Sexually Transmitted Diseases
Verified
Journal Article
Open access
ISIrene A. Stafford
Irene A. Stafford
CBCarrie Bakunas
Carrie Bakunas
JHJoe Haydamous
Joe Haydamous
AMAna Mosqueda
Ana Mosqueda
JKJeffrey D. Klausner
Jeffrey D. Klausner
SBSean C. Blackwell
Sean C. Blackwell
Background: Adult and congenital syphilis rates are rising in the United States. The aim of this pre- and post-implementation study was to determine whether implementation of an opt-out laboratory-based and rapid syphilis point-of-care testing program in the emergency department (ED) improves the detection and treatment of syphilis during pregnancy in a high-prevalence region. Methods: This pre- and post-implementation study was conducted at the University of Texas Health Science Center, Houston, TX. During the pre-implementation phase (November 1, 2023–February 29, 2024), pregnant patients presenting to the ED underwent laboratory-based syphilis testing using the reverse algorithm only when clinically indicated. In the post-implementation phase (March 1, 2024–June 25, 2024), pregnant patients without prenatal care or with no documented syphilis result underwent opt-out syphilis testing using the Syphilis Health Check point-of-care test and the laboratory-based reverse syphilis testing algorithm. Patients with positive syphilis test results were treated by providers. All results were confirmed with the laboratory-based test, and patient follow-up was scheduled. Results: During the pre-implementation period, 302 pregnant patients presented to the ED, and only 6 (2%) underwent syphilis laboratory-based testing, none of which yielded positive results. In the post-implementation period, 322 pregnant patients presented to the ED and 202 (62.7%) were approached. Of these, 114 (56.4%) were tested using either the Syphilis Health Check or laboratory-based reverse algorithm (P < 0.001). Four patients tested positive for syphilis, indicating a prevalence of 3.5%. Conclusions: An opt-out and rapid syphilis testing program for pregnant individuals visiting the ED increased syphilis screening from 2% to 56.4%, and detected syphilis that might have otherwise been missed.

23 April 2009 in American Journal of Perinatology
Verified
Journal Article
Closed access
SBSean C. Blackwell
Sean C. Blackwell
LTLatricia Thompson
Latricia Thompson
JRJerrie Refuerzo
Jerrie Refuerzo
We sought to determine the rate and timing of full publication of clinical trials initially presented as abstracts at a national maternal-fetal medicine (MFM) research meeting and identify factors associated with publication status. All abstracts presented over a 3-year period (2000 to 2002) at the Society of MFM Annual Meeting were reviewed. Abstracts reporting outcomes for prospective, interventional research studies with human subjects were included. Multiple electronic databases were searched for evidence of full publication with a minimum of 5-year follow-up. The reporting characteristics of abstracts that were published as full research reports were compared with those not published. During the study period, 2012 abstracts were presented and 90 met all study criteria (4.5%). Of these, 55.6% (n = 50) were subsequently published as full research reports. There were no differences in the use of placebo, randomization, or blinding. Studies reaching full publication had larger sample size (median 174 [12 to 4165] versus 96 [22 to 1039]; p = 0.02) and were more likely to report treatment differences (60% versus 32.5% p = 0.009). After adjusting for confounding factors, the reporting of treatment differences remained associated with full publication (odds ratio 3.3 [95% confidence interval 1.3 to 8.0]; p = 0.01). Full publication of clinical trials occurred more often if treatment differences were present. Positive publication bias exists in MFM research.